Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Sumitomo Pharma Co., Ltd., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan. Established in 1897, the company has a rich history marked by significant milestones, including its expansion into global markets and a commitment to innovative healthcare solutions.
With a focus on research and development, Sumitomo Pharma excels in areas such as central nervous system disorders, oncology, and infectious diseases. Its core products are distinguished by their efficacy and safety, addressing critical health needs worldwide.
Recognised for its strong market position, Sumitomo Pharma continues to achieve notable advancements in drug development, contributing to improved patient outcomes. The company’s dedication to innovation and quality solidifies its reputation as a leader in the pharmaceutical industry.
+10 vs industry average
Sumitomo Pharma Co., Ltd.’s score of 50 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Sumitomo Pharma Co., Ltd., a pharmaceutical preparation manufacturer headquartered in Japan, has set ambitious targets to reduce its greenhouse gas (GHG) emissions. For the fiscal year 2024, the company reported a total of approximately 312.6 million kg CO2e across Scope 1, 2, and 3 emissions. This includes Scope 1 emissions of around 23.1 million kg CO2e, Scope 2 emissions of approximately 23.2 million kg CO2e, and Scope 3 emissions totalling about 268.3 million kg CO2e.
In fiscal year 2023, Sumitomo Pharma's total emissions were approximately 435.7 million kg CO2e, comprising 27
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 2
Sumitomo Pharma Co., Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2020 base year. Sumitomo Pharma Co.,…
2030
42% reduction in Scope 1
Sumitomo Pharma Co., Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2020 base year. Sumitomo Pharma Co.,…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


Common questions about Sumitomo Pharma Co., Ltd.’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more